Clinical Use of Ruxolitinib in an Academic Medical Center in Unselected Patients With Myeloproliferative Neoplasms not on Clinical Study
Ruxolitinib is the only approved therapy for myelofibrosis. However, its use in patients with myeloproliferative neoplasms not participating in clinical studies has been poorly described. The researchers reviewed the medical records of 45 patients and found ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate).
Leuk Lymphoma
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology